The Biotherapies and Bioproduction of Innovative Therapies (BBTI) Research Program (PEPR), launched by the French government in 2021, is one of the major initiatives in the Biotherapies and Bioproduction of Innovative Therapies acceleration strategy of the France 2030 plan.
This research program, whose scientific management has been entrusted to Inserm and CEA, aims to contribute to the development of tomorrow’s biotherapies and associated key technologies.
It also aims to federate the national academic research ecosystem and promotes close links with industry and hospitals.
The PEPR is part of a wider drive to consolidate France’s leadership and competitiveness in this sector research and manufacturing processes.
Latest news
SynBioTherapy : Revolutionizing biotherapies through synthetic biology
27th november 2024 Learning Planet Institute, Paris This one-day event, co-organized by the DIM BioConvS and the PEPR Biotherapy and Bioproduction, will bring together experts in synthetic biology and biotherapy to explore the synergies between these two fields. Thanks to generous funding from Genopole, this conference aims to showcase innovations, encourage interdisciplinary collaboration and initiate…
PEPR participation to the 9th Bioproduction Congress (BIOPC2024)
25th – 26th september 2024 Palais des Congrès, Tours – France Why the PEPR participate? The BIOPC2024 will be the perfect occasion to connect and discuss with experts from companies and academia about needs and initiative to support the development of innovative biotherapeutics, including mAbs, vaccines, cell therapy and novel products, and to support their…
PEPR Biotherapies’ first call for projects
Opening : 15 april 2024 – Deadline : 5 september 2024
Projects
BACTER-EV-BOOSTER
Multidisciplinary approach to stimulate the bioproduction and engineering of Gram+ bacteria’s Extracellular Vesicles (EVs) for therapeutic applications to treat inflammation
Bioengineered Skin-France
Bioengineering of next-generation skin substitutes for cutaneous regeneration
BIOSCALE
Improving the whole chain of large scale AAV bioproduction through disruptive technologies
CARN
Development of biotherapies based on the local delivery of therapeutic RNAs by hybrid functionalized extracellular vesicles (EVs) for musculoskeletal regeneration
iPSC France
Genomic editing of stable universal pluripotent stem cells for allogeneic cell biotherapies
QualAAV
Innovative approaches for quality control to support the industrial deployment of future gene therapy products.
STROMAEV
From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation
